Colon Cancer, Liver Metastases, Rectal Cancer
Conditions
Keywords
colorectal cancer, liver metastasis, bevacizumab
Brief summary
Colorectal carcinoma with liver metastasis is one of the major problems bothering physicians worldwide. Bevacizumab combined with chemotherapy is the standard treatment recommended by several guidelines. Despite the high cost, a certain portion of patients couldn't benefit from this therapy. This study is aiming to find out the specific type of patients who would respond to bevacizumab by Radiomics approach, and evaluate the prediction value of this imaging model with clinical and genetic factors.
Interventions
DRUGBevacizumab
bevacizumab combined with chemotherapy
Sponsors
Peking University People's Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Colorectal carcinoma confirmed by pathological result. 2. Liver metastasis confirmed by imaging studies. 3. Treatment of bevacizumab combined with chemotherapy chosen by MDT team. 4. ECOG: 0-2. 5. Normal laboratory studies including liver\\renal\\bone marrow functions. 6. Expected lifespan more than 3 months.
Exclusion criteria
1. Previous treatment of colorectal cancer with liver metastasis. 2. Diagnosed with other malignancies. 3. Couldn't finish the trial due to several reasons such as allergy to chemotherapy drugs\\pregnancy or lactation\\chronic heart disease\\unable to sustain further treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| estimated ORR | 6-8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| estimated PFS | 3 years |
| estimated OS | 3 years |
Countries
China
Contacts
Primary ContactYudi Bao, MD
Outcome results
None listed